Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL RECOMBINANT PEPTIDES INDUSTRY
2.1 Summary about Recombinant Peptides Industry
2.2 Recombinant Peptides Market Trends
2.2.1 Recombinant Peptides Production & Consumption Trends
2.2.2 Recombinant Peptides Demand Structure Trends
2.3 Recombinant Peptides Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Glucagon
4.2.2 Calcitonin
4.2.3 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Oncology
4.3.2 Blood Disorders
4.3.3 Infectious Diseases
4.3.4 Autoimmune Diseases
4.3.5 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Glucagon
5.2.2 Calcitonin
5.2.3 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Oncology
5.3.2 Blood Disorders
5.3.3 Infectious Diseases
5.3.4 Autoimmune Diseases
5.3.5 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Glucagon
6.2.2 Calcitonin
6.2.3 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Oncology
6.3.2 Blood Disorders
6.3.3 Infectious Diseases
6.3.4 Autoimmune Diseases
6.3.5 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Glucagon
7.2.2 Calcitonin
7.2.3 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Oncology
7.3.2 Blood Disorders
7.3.3 Infectious Diseases
7.3.4 Autoimmune Diseases
7.3.5 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Glucagon
8.2.2 Calcitonin
8.2.3 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Oncology
8.3.2 Blood Disorders
8.3.3 Infectious Diseases
8.3.4 Autoimmune Diseases
8.3.5 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Glucagon
9.2.2 Calcitonin
9.2.3 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Oncology
9.3.2 Blood Disorders
9.3.3 Infectious Diseases
9.3.4 Autoimmune Diseases
9.3.5 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Sandoz Pharma
10.1.2 Stada Arzneimittel
10.1.3 Amgen
10.1.4 Hospira
10.1.5 Actavis
10.1.6 Cipla Ltd.
10.1.7 Wockhardt Ltd.
10.1.8 Biocon Ltd.
10.2 Recombinant Peptides Sales Date of Major Players (2017-2020e)
10.2.1 Sandoz Pharma
10.2.2 Stada Arzneimittel
10.2.3 Amgen
10.2.4 Hospira
10.2.5 Actavis
10.2.6 Cipla Ltd.
10.2.7 Wockhardt Ltd.
10.2.8 Biocon Ltd.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
1.Table Recombinant Peptides Product Type Overview
2.Table Recombinant Peptides Product Type Market Share List
3.Table Recombinant Peptides Product Type of Major Players
4.Table Brief Introduction of Sandoz Pharma
5.Table Brief Introduction of Stada Arzneimittel
6.Table Brief Introduction of Amgen
7.Table Brief Introduction of Hospira
8.Table Brief Introduction of Actavis
9.Table Brief Introduction of Cipla Ltd.
10.Table Brief Introduction of Wockhardt Ltd.
11.Table Brief Introduction of Biocon Ltd.
12.Table Products & Services of Sandoz Pharma
13.Table Products & Services of Stada Arzneimittel
14.Table Products & Services of Amgen
15.Table Products & Services of Hospira
16.Table Products & Services of Actavis
17.Table Products & Services of Cipla Ltd.
18.Table Products & Services of Wockhardt Ltd.
19.Table Products & Services of Biocon Ltd.
20.Table Market Distribution of Major Players
21.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
22.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
23.Table Global Recombinant Peptides Market Forecast (Million USD) by Region 2021f-2026f
24.Table Global Recombinant Peptides Market Forecast (Million USD) Share by Region 2021f-2026f
25.Table Global Recombinant Peptides Market Forecast (Million USD) by Demand 2021f-2026f
26.Table Global Recombinant Peptides Market Forecast (Million USD) Share by Demand 2021f-2026f